Sitagliptin, by enhancing insulin secretion and decreasing glucagon levels, can complement insulin therapy effectively, optimizing blood glucose control in new insulin users.

Combining Sitagliptin with insulin in new insulin-dependent diabetics helps fine-tune blood sugar management by boosting the insulin’s glucose-lowering effect.

Adding Sitagliptin to insulin regimens in newly insulin-dependent patients can improve glycemic control by increasing insulin production in response to meals.